advertisement
Erigeron Breviscapus Hand-Mazz (EBHM) is a herb that has often been used by Chinese people over the centuries: it possesses the ability to inhibit blood coagulation, enhance the microcirculation, and dilate brain blood vessels, as is evidenced by its clinical application in the treatment of brain thrombosis and associated paralysis, myocardial ischemia and coronary arteriosclerosis.
Experience with EBHM in glaucoma is based on two clinical trials which took place in the early 1990s, and on several laboratory studies.
In the clinical trials, glaucoma patients with controlled IOP after trabeculectomy were divided into an EBHM group and a placebo group. After six months of treatment, the EBHM group did better than the placebo group, as measured by object V/4/e of the Goldmann Perimeter in the Esterman grid.
A similar study was performed using the Oculus Automated Perimeter. Again,
the visual fields improved significantly in the treatment group (mean sensitivity
+1.42 dB versus -0.95 dB in the placebo group after six months). The herb
had no side-effects.
In rats with induced OHT, EBHM was injected intramuscularly one week prior
to, and three weeks post-, OHT. The treated group did significantly better
using the cytochrome oxidase technique for RGC survival. Positive results
were also reported in axoplamic flow studies and after partial optic nerve
crush injuries. Finally, EBHM was shown to have a partial neuroprotective
effect on NMDA-induced neuronal (retinal ganglion cell layer) loss in rats.
Professor Jiang concluded that EBHM seems to have a neuroprotective effect in glaucoma. Studies of longer duration are needed in order to demonstrate a more pertinent effect of EBHM in human glaucoma. The molecular mechanism of the drug also needs further investigation.
References